Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Benserazide inhibits the enzyme that converts levodopa to dopamine outside the brain, ensuring more levodopa reaches the central nervous system where it can be transformed into dopamine.

The appropriate dose of Madopar is individualized. A qualified prescriber determines the starting amount and any subsequent adjustments based on the patient’s clinical response, age, disease severity and concomitant therapies. Patients should follow the prescribing physician’s instructions and not alter the dose on their own.

Safety data for Madopar during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers typically advise discontinuation or careful monitoring if treatment is considered during these periods.

To request Madopar, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Madopar combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. This can lead to more consistent symptom control and potentially lower doses. Compared with dopamine agonists, Madopar provides a more direct dopamine replacement but may have a higher risk of motor complications such as dyskinesia.

Madopar tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Madopar is taken orally with a full glass of water. It can be taken with or without food, but high‑protein meals may interfere with absorption, so spacing the dose away from such meals is often recommended. Tablets should be swallowed whole; they are not intended for crushing or chewing.

Serious risks include the development of dyskinesia (involuntary movements), severe hypotension, cardiac arrhythmias, and psychiatric effects such as hallucinations or severe mood changes. Patients should seek immediate medical attention if they experience sudden confusion, severe dizziness, uncontrolled movements, or signs of an allergic reaction.

Madopar is contraindicated in individuals with known hypersensitivity to levodopa, benserazide or any excipients, as well as patients taking non‑selective MAO inhibitors. Caution is advised for those with narrow‑angle glaucoma, severe cardiovascular disease, or a history of malignant neuroleptic syndrome. A healthcare professional must evaluate suitability before prescribing.